Toru Kiguchi

Saitama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Journal: Cureus

Published: January 29, 2026

Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study.

Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study.

Journal: International journal of molecular sciences

Published: January 09, 2026

COVID-19 Infection in Patients with Follicular Lymphoma and Related Indolent B-Cell Lymphomas Receiving Anti-CD20 Monoclonal Antibody Maintenance Therapy.

COVID-19 Infection in Patients with Follicular Lymphoma and Related Indolent B-Cell Lymphomas Receiving Anti-CD20 Monoclonal Antibody Maintenance Therapy.

Journal: Acta haematologica

Published: October 11, 2025

A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm.

A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm.

Journal: International journal of hematology

Published: July 27, 2025

Correction: Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.

Correction: Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.

Journal: International journal of hematology

Published: April 11, 2025

Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.

Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: May 15, 2024

Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.

Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.

Journal: International journal of hematology

Published: January 26, 2024

Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.

Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.

Journal: International journal of hematology

Published: November 19, 2023

A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m + AML in Japan.

A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m + AML in Japan.

Journal: Current medical research and opinion

Published: October 26, 2023

First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants.

First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants.

Journal: International journal of hematology

Published: July 05, 2023

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.

Journal: Blood advances

Published: December 19, 2022

Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.

Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.

Journal: Hematological oncology

Published: August 23, 2022

Showing 1-12 of 49

Last Updated: 09/26/2026